

# LanthaScreen® TR-FRET tyrosine kinase and protein kinase C assay

Randy Hoffman<sup>1</sup>, Megan Buros<sup>1</sup>, Kevin Kupcho<sup>1</sup> and E.J. Dell<sup>2</sup>  
<sup>1</sup>Invitrogen Corporation <sup>2</sup>BMG LABTECH

- Dual wavelength detection of terbium and fluorescein using dedicated optic settings
- Strong and long-lasting donor signal minimizes background
- Rapid and reliable detection of PKC's and tyrosine kinase activity

## Introduction

Protein Kinase C (PKC) enzymes are a diverse family of enzymes that under specific signaling conditions phosphorylate proteins on serine and threonine amino acids. PKCs are involved in many cellular functions including neuronal activity, cell growth, cell proliferation, and cell movement, as well as in several diseases including cardiovascular, cancer, diabetes, and Alzheimer's. Therefore a TR-FRET screening assay, such as the one described here, can aid in further elucidating PKC's function.

Tyrosine kinases (TKs) are a diverse family of enzymes that under specific signaling conditions phosphorylate proteins on the amino acid tyrosine. TKs are involved in many cellular functions such as cell division and cell proliferation, as well as in several diseases including cancer and diabetes. Tyrosine kinases play important roles in cell growth, thereby making them important drug targets in cancer therapy. For that reason a TR-FRET screening assay, such as the one described here, can aid in elucidating specific inhibitors for tyrosine kinases.

## Assay Principle

A fluorescein labeled poly-GT or poly-GAT [Glu, Ala, Tyr] substrate is incubated with a tyrosine kinase and ATP. For protein kinase C assays a fluorescein labeled PKC substrate is incubated with PKC and ATP. Subsequently, a terbium labeled antibody that binds to the phosphorylated form of the substrate is added. When the antibody interacts with the phosphorylated substrate, FRET will occur between the terbium label (emits at 490 nm) and the fluorescein moiety (emits at 520 nm) (Figure 1).




Fig. 1: LanthaScreen™ TR-FRET assay principle for a tyrosine kinase (TK) assay.

Measurements are taken at 490 and 520 nm and the 520/490 ratio is plotted versus the concentration of enzyme to determine an EC<sub>50</sub> for the enzyme and its substrate.

## Materials & Methods

- Invitrogen's Fluorescein PKC Substrate and PKC Kinase Buffer (5x), PKC $\alpha$ , Kinase Quench Buffer
- Invitrogen's LanthaScreen™ Tb-PKC Substrate Antibody
- Invitrogen's Fluorescein-poly-GT and Fluorescein-poly-GAT, Tyrosine Kinase Buffer, ZAP70, Screen Dilution Buffer
- Invitrogen's LanthaScreen® Tb-PY20 Antibody
- black Corning® low volume 384-well microplate

### PKC Titration

Multiple PKC isoforms were titrated to determine optimal kinase concentrations for screening. The following protocol is an example of the conditions used to determine the EC<sub>50</sub> of PKC $\alpha$  and its substrate.

A dilution series of PKC $\alpha$ , starting at a final concentration of 2.0  $\mu$ g/ml, was incubated in the presence of 250 nM fluorescein-labeled PKC substrate and 20  $\mu$ M ATP in a total volume of 10  $\mu$ l in a microplate. After a 90-minute incubation at room temperature, 10  $\mu$ l of TR-FRET dilution buffer containing 2X EDTA (20 mM) and 2X Tb-PKC antibody (1.0 nM) was added and mixed to create a final volume of 20  $\mu$ l per well, a final 1X EDTA concentration of 10 mM, and a final 1X antibody concentration of 0.5 nM. After incubating for 60 minutes at room temperature, the plate was read on the BMG LABTECH microplate reader. Each data point represents the average of three wells.

### Tyrosine Kinase Titration

To demonstrate the functionality of a universal tyrosine kinase assay using LanthaScreen™, both fluorescein-poly-GAT [Glu, Ala, Tyr] and fluorescein-poly-GT [Glu, Tyr] substrates were used with terbium labeled PY20 antibody.


A dilution series of kinase was incubated with 400 nM fluorescein labeled substrate and 200  $\mu$ M ATP in a total volume of 10  $\mu$ l in a microplate. After 60 mins of incubation at room temperature, 5  $\mu$ l of TR-FRET dilution buffer containing 4X EDTA (60 mM) was added. Next, 5  $\mu$ l of TR-FRET dilution buffer with 4X antibody (8 nM) was added and mixed to create a final volume of 20  $\mu$ l per well, a final 1X EDTA concentration of 15 mM, and a final 1X antibody concentration of 2 nM. After 60 mins of incubation at room temperature, the plate was read in the microplate reader.

## Instrument settings

	FLUOstar®/ POLARstar® Omega	CLARIOstar®	PHERASTAR® FS
Detection mode	Time-resolved Fluorescence		
Method	Endpoint, Top optic		
Optic settings	Advanced TRF Optic Head Ex-Filter: TREX Em-FilterA: Em520 Em-FilterB: 490-10	Ex-Filter: Ex TR Em-FilterA: 520-10 Em-FilterB: 490-10	LanthaScreen Optic module: 337 520 490
Integration start	100 µs		
Integration time	200 µs		

## Results & Discussion

Figure 2 shows representative kinase titration curves for PKC $\alpha$  and PKC $\zeta$ .



**Fig. 2:** LanthaScreen™ monitored on the PHERAstar FS: PKC $\alpha$  and PKC $\zeta$  titrations


Table 1 shows statistical data for all kinases tested.

**Table 1:** LanthaScreen™ on the PHERAstar: statistics for PKC isoform titrations.

	PKC $\alpha$	PK-C $\beta$ I	PKC- $\beta$ II	PKC $\delta$	PKC $\epsilon$	PKCO	PKC $\zeta$
EC <sub>50</sub> (ng/ml)	0.43	0.27	0.22	0.07	0.03	0.16	0.12
Min. Value	0.44	0.43	0.79	0.55	0.73	1.02	0.84
Max. Value	2.69	2.66	2.61	2.64	2.63	2.63	2.63
Max-min	2.25	2.23	1.82	2.09	1.90	1.61	1.79
Fold Diff (max/min)	6.1	6.2	3.3	4.8	3.6	2.6	3.1
Hill Slope	1.1	0.89	1.01	0.70	0.93	0.96	0.83
R <sup>2</sup>	0.991	0.996	0.988	0.979	0.988	0.976	0.982
S:N	60	47	18	31	25	14	18
Z'-factor value	0.94	0.91	0.78	0.87	0.85	0.74	0.79

All PKC isoenzymes were titrated in a similar manner as PKC $\alpha$ . Regardless of "fold difference" or signal-to-noise ratios, all assays provided Z' values far greater than 0.5. This is due to the use of FRET-based, ratiometric data analysis, which leads to low standard deviations of the replicates. Both hill slope and R<sup>2</sup> measurements fall within acceptable limits. R<sup>2</sup> values approaching 1.0 indicate a perfect curve fit.

In figure 3 kinase titration curves for ZAP-70 are presented (Fig. 3A+B).



**Fig. 3:** LanthaScreen™ assay was measured on the PHERAstar FS for tyrosine kinase ZAP-70 at different concentrations and for different substrates. **A** The fluorescein-labeled poly GAT substrate is used. **B** The substrate is a fluorescein-labeled poly GT substrate.

The results show that use of a fluorescein-labeled substrate common for many TKs (poly-GT or poly-GAT) allows for the development of a "universal" TK assay using the LanthaScreen™ format.

## Conclusion

Invitrogen's terbium-based LanthaScreen™ can easily be measured on BMG LABTECH instrumentation. The assay shows several advantages:


- The ratiometric nature of LanthaScreen™ assay eliminates well to well variation.
- The time-resolved nature allows for the use of fluorescein without the associated drawbacks of compound interference.
- The ability to use fluorescein simplifies assay development and costs.



PHERAstar® FSX  
PHERAstar® FS



CLARIOstar®



Omega Series